Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma

Melanoma and Skin Cancer

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

N Engl J Med.

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators

doi: 10.1056/NEJMoa1709030.

Melanoma and Skin Cancer

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases

Ann Surg Oncol.

Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Stern S, Elashoff R, Gammon G, Morton DL; MMAIT-IV Clinical Trial Group

doi: 10.1245/s10434-017-6072-3.

Melanoma and Skin Cancer

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

Eur J Cancer

Eggermont AM, Meshcheryakov A, Atkinson V, Blank CU, Mandala M, Long GV, Barrow C, Di Giacomo AM, Fisher R, Sandhu S, Kudchadkar R, Ortiz Romero PL, Svane IM, Larkin J, Puig S, Hersey P, Quaglino P, Queirolo P, Stroyakovskiy D, Bastholt L, Mohr P, Hernberg M, Chiarion-Sileni V, Strother M, Hauschild A, Yamazaki N, van Akkooi AC, Lorigan P, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C

doi: 10.1016/j.ejca.2021.09.023

Melanoma and Skin Cancer

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

N Engl J Med.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J

doi: 10.1056/NEJMoa1709684.

Melanoma and Skin Cancer

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

J Clin Oncol.

Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA

doi: 10.1200/JCO.2017.73.2289.

Psoriasis

Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials

Value Health.

Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE

doi: 10.1016/j.jval.2017.05.025.

Psoriasis

Calcipotriol plus betamethasone dipropionate aerosol foam versus apremilast, methotrexate, acitretin, or fumaric acid esters for the treatment of plaque psoriasis: A matching-adjusted indirect comparison

J Eur Acad Dermatol Venereol.

Bewley A, Shear NH, Calzavara-Pinton PG, Hansen JB, Nyeland ME, Signorovitch J

doi: 10.1111/jdv.15369.

Melanoma and Skin Cancer

Life-threatening polymyositis with spontaneous hematoma induced by nivolumab in a patient with previously resected melanoma

Melanoma Res

Liu WK, Naban N, Kaul A, Patel N, Fusi A

doi: 10.1097/CMR.0000000000000706

COMMENTED

Melanoma and Skin Cancer

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

JAMA Oncol.

Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain JF, Hodi FS, Wolchok JD

doi: 10.1001/

Related content

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials

Calcipotriol plus betamethasone dipropionate aerosol foam versus apremilast, methotrexate, acitretin, or fumaric acid esters for the treatment of plaque psoriasis: A matching-adjusted indirect comparison

Life-threatening polymyositis with spontaneous hematoma induced by nivolumab in a patient with previously resected melanoma

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials